micro-community-banner
  • Saved

3yr
Shared decision-making in treating hyperlipidemia

Cholesterol management has evolved to become increasingly complex and individualized. Newer guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) detail risk assessment, novel non-statin treatment options, concerns centered on patient subgroups, and the value of therapy.



Treatment plans are now highly personalized, and experts recommend shared decision-making to fulfill patient needs. When discussing cholesterol management with patients, 4 tenets to keep in mind include the following:




  1. stress the importance of a heart-healthy lifestyle spanning the patient’s life;

  2. discuss the 10-year risk of atherosclerotic cardiovascular disease per the Pooled Cohort Equations, as well as mitigating risk factors;

  3. explain that although statins are the foundation of treatment, add-on options are available for patients on maximally tolerated statins who need to further lower their LDL-C levels;

  4. address special treatment algorithms in at-risk patient subgroups.



What has worked for you when advising patients on lipid-lowering therapy? What role does shared decision-making play when caring for your patients with hyperlipidemia?


  • 3yr
    Shared decision making giving patients an active role in their Rxs is more likely making patients more responsible and compliant, therefore it is a win win situation
  • 3yr
    Shared decision making is critical so that patients feel empowered and are more likely to be compliant. Patients are often reluctant to try statin medications but maybe willing to Show More

Show More Comments

  • Saved

3yr
Shared decision-making in treating hyperlipidemia

Cholesterol management has evolved to become increasingly complex and individualized. Newer guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) detail risk assessment, novel non-statin treatment options, concerns centered on patient subgroups, and the value of therapy.



Treatment plans are now highly personalized, and experts recommend shared decision-making to fulfill patient needs. When discussing cholesterol management with patients, 4 tenets to keep in mind include the following:




  1. stress the importance of a heart-healthy lifestyle spanning the patient’s life;

  2. discuss the 10-year risk of atherosclerotic cardiovascular disease per the Pooled Cohort Equations, as well as mitigating risk factors;

  3. explain that although statins are the foundation of treatment, add-on options are available for patients on maximally tolerated statins who need to further lower their LDL-C levels;

  4. address special treatment algorithms in at-risk patient subgroups.



What has worked for you when advising patients on lipid-lowering therapy? What role does shared decision-making play when caring for your patients with hyperlipidemia?


  • 3yr
    Shared decision making giving patients an active role in their Rxs is more likely making patients more responsible and compliant, therefore it is a win win situation
  • 3yr
    Shared decision making is critical so that patients feel empowered and are more likely to be compliant. Patients are often reluctant to try statin medications but maybe willing to Show More

Show More Comments

  • Saved

3yr
New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention - PubMed

New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36213094/

doi: 10.1007/s12170-022-00694-y. 1 Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. doi: 10.1007/s12170-022-00694-y. 1 Ciccarone Center for the...


Conclusions: Recently several novel LDL-C lowering medications have been approved. New therapeutic targets have been identified and present additional means of lowering LDL-C and other atherogenic compounds for patients who remain at high ASCVD risk.

  • Saved

3yr
Antiplatelet therapy at discharge and long-term prognosis in Takotsubo syndrome: Insights from the Spanish National Registry (RETAKO)

Antiplatelet therapy at discharge and long-term prognosis in Takotsubo syndrome: Insights from the Spanish National Registry (RETAKO)

Source : https://www.sciencedirect.com/science/article/pii/S0870255122003596?via=ihub

Available online 12 October 2022 Endothelial dysfunction and platelet activation have been highlighted as possible mediators in Takotsubo syndrome (TTS). Nevertheless, to date, evidence on the usefulness of antiplatelet therapy...

/>

Conclusions: "Conclusion: Patients with TTS receiving APT at discharge presented better prognosis up to two-years of follow-up compared with their counterparts not receiving APT."

  • Saved

3yr
A low-frequency APOB p.(Pro955Ser) variant contributes to the severity of/variability in familial hypercholesterolemia - PubMed

A low-frequency APOB p.(Pro955Ser) variant contributes to the severity of/variability in familial hypercholesterolemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36190978/

The low-frequency APOB c.2863C > T:p.(Pro955Ser) variant is not an FH-causative variant, but it has a moderate effect size in HeFH. These findings suggest that the combination of the APOB...


Conclusions: The low-frequency APOB c.2863C > T:p.(Pro955Ser) variant is not an FH-causative variant, but it has a moderate effect size in HeFH. These findings suggest that the combination of the APOB c.2863C > T:p.(Pro955Ser) variant and age, environmental factors or other genetic factors contributes to the severity of or...